I. Marschner

V. Gebski, I. Marschner, L. Sequist, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.

J M Taylor, L A Kalish, J. Ioannidis, 1998, Statistics in medicine.

Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.

I. Marschner, R. Simes, D. Goldstein, 2019, Pancreas.

Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases.

R A Betensky, S. Hammer, I. Marschner, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Long-term risk stratification for survivors of acute coronary syndromes - Results from the long-term intervention with pravastatin in ischemic disease (LIPID) study

I. Marschner, H. White, P. Glasziou, 2001 .

Relationship Between Lipid Levels and Clinical Outcomes in the Long-Term Intervention With Pravastatin in Ischemic Disease (LIPID) Trial: To What Extent Is the Reduction in Coronary Events With Pravastatin Explained by On-Study Lipid Levels?

A. Keech, I. Marschner, H. White, 2002, Circulation.

Parametric conditional frailty models for recurrent cardiovascular events in the lipid study

I. Marschner, A. Tonkin, J. Simes, 2008, Clinical trials.

Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.

A. Keech, I. Marschner, H. White, 2004, European heart journal.

Validation of Progression-Free Survival Rate at 6 Months and Objective Response for Estimating Overall Survival in Immune Checkpoint Inhibitor Trials

I. Marschner, M. Friedlander, J. Simes, 2020, JAMA network open.

Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

V. Gebski, I. Marschner, S. Loi, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).

I. Marschner, M. Chatfield, J. Simes, 2012 .

Regional differences in multinational clinical trials: anticipating chance variation

Ian C Marschner, I. Marschner, 2010, Clinical trials.

Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.

R. Califf, R. Diaz, I. Marschner, 2010, American heart journal.

Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudies

I. Marschner, J. Simes, S. Galbraith, 2006, Statistics in medicine.

Stable computational methods for additive binomial models with application to adjusted risk differences

Ian C. Marschner, Mark W. Donoghoe, I. Marschner, 2014, Comput. Stat. Data Anal..

Stratified additive Poisson models: Computational methods and applications in clinical epidemiology

Ian C. Marschner, Alexandra C. Gillett, Rachel L. O'Connell, 2012, Comput. Stat. Data Anal..

Relative risk regression: reliable and flexible methods for log-binomial models.

I. C. Marschner, A. C. Gillett, I. Marschner, 2012, Biostatistics.

glm2: Fitting Generalized Linear Models with Convergence Problems

Ian C. Marschner, I. Marschner, 2011, R J..

Exertional oxygen of limited benefit in patients with chronic obstructive pulmonary disease and mild hypoxemia.

I. Marschner, C. McDonald, C. Barter, 1995, American journal of respiratory and critical care medicine.

Pre‐ and on‐treatment lactate dehydrogenase as a prognostic and predictive biomarker in advanced non–small cell lung cancer

I. Marschner, S. Lord, T. John, 2022, Cancer.

Anticoagulation Strategies in Non-Critically Ill Patients with Covid-19.

G. Kang, I. Marschner, D. Christopher, 2022, NEJM evidence.

Stable Computation of Maximum Likelihood Estimates in Identity Link Poisson Regression

Ian C. Marschner, I. Marschner, 2010 .

Assessment of Statistical Heterogeneity in the PLATO Trial

I. Marschner, M. Buyse, 2011, Cardiology.

Pregabalin versus gabapentin in partial epilepsy: a meta-analysis of dose-response relationships

I. Marschner, P. Delahoy, S. Thompson, 2010, BMC neurology.

Circulating Cystatin C Is an Independent Risk Marker for Cardiovascular Outcomes, Development of Renal Impairment, and Long‐Term Mortality in Patients With Stable Coronary Heart Disease: The LIPID Study

I. Marschner, H. White, S. Blankenberg, 2022, Journal of the American Heart Association.

Optimal design of clinical trials comparing several treatments with a control

Ian C Marschner, I. Marschner, 2007, Pharmaceutical statistics.

The association between El Niño/Southern Oscillation events and typhoons in the Marshall Islands.

I. Marschner, D. Spennemann, 1995, Disasters.

Importance of sequential methods in meta-analysis: implications for postoperative mortality, delirium, and stroke management.

I. Marschner, J. Loadsman, Thomas Payne, 2023, British journal of anaesthesia.

To guide future practice, perinatal trials should be much larger, simpler and less fragile with close to 100% ascertainment of mortality and other key outcomes.

I. Marschner, J. Simes, W. Tarnow-Mordi, 2023, Seminars in perinatology.

Estimation of adjusted rate differences using additive negative binomial regression

I. Marschner, M. Donoghoe, 2016, Statistics in medicine.

Unpacking the behavioural components and delivery features of early childhood obesity prevention interventions in the TOPCHILD Collaboration: a systematic review and intervention coding protocol

A. M. Linares, I. Marschner, K. Hesketh, 2020, BMJ Open.

Linear mixed models for investigating effect modification in subgroup meta-analysis

I. Marschner, A. L. Sørensen, 2023, Statistical methods in medical research.

Correlation of phase 2 trials (Ph2t) results with outcomes of phase 3 trials (Ph3t) of investigational agents (IA) in locally advanced and metastatic pancreas cancer (LAMPC).

I. Marschner, D. Goldstein, J. Simes, 2017 .

The effect of heterogeneity on the spread of disease

Ian C. Marschner, I. Marschner, N. Becker, 1990 .

Specifying objectives and outcomes for clinical trials

V. Gebski, A. Keech, I. Marschner, 2002, The Medical journal of Australia.

Relative Risk Regression for Binary Outcomes: Methods and Recommendations

I. Marschner, 2015 .

Deterioration of detectable human immunodeficiency virus serum p24 antigen in samples stored for batch testing

I. Marschner, S. Spector, J. Lathey, 1997, Journal of clinical microbiology.

Pulse Oximeter Saturation Targeting and Oximeter Changes in the Benefits of Oxygen Saturation Targeting (BOOST)‐II Australia and BOOST‐II UK Oxygen Trials

P. Davis, I. Marschner, J. Simes, 2019, The Journal of pediatrics.

NIAID Workshop, Memphis, Tennessee, 25-26 March 1997: Statistical issues for HIV surrogate endpoints: Point/counterpoint

John P. A. Ioannidis, Michael Hughes, Jeffrey M. Albert, 1998 .

Parameter expansion for fitting regression models with non-negativity constraints

I. Marschner, M. Donoghoe, 2022, Communications in Statistics - Simulation and Computation.

A new algorithm for fitting semi-parametric variance regression models

Ian C. Marschner, Kristy P. Robledo, I. Marschner, 2021, Computational Statistics.

Combinatorial EM algorithms

Ian C. Marschner, I. Marschner, 2013, Statistics and Computing.

Continued lamivudine versus delavirdine in combination with indinavir and zidovudine or stavudine in lamivudine-experienced patients: results of Adult AIDS Clinical Trials Group protocol 370

C. Pettinelli, I. Marschner, V. Johnson, 2000, AIDS.

International differences in patients, care and outcomes associated with acute myocardial infarction (AMI): the HERO-2 trial

R. Diaz, I. Marschner, H. White, 2003 .

A method for assessing age-time disease incidence using serial prevalence data.

I. Marschner, Ian C. Marschner, 1997, Biometrics.

ROBUST ANALYSIS OF THE BIFURCATING AUTOREGRESSIVE MODEL IN CELL LINEAGE STUDIES

Richard M. Huggins, Ian C. Marschner, I. Marschner, 1991 .

Uric acid predicts long‐term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study

V. Gebski, A. Keech, I. Marschner, 2020, Diabetes, obesity & metabolism.

The ascending testis

I. Marschner, A. Woodward, I. Hudson, 2004, Pediatric Surgery International.

Sensitivity analyses assessing the impact of early stopping on systematic reviews: Recommendations for interpreting guidelines

I. Marschner, L. Askie, I. M. Schou, 2020, Research synthesis methods.

Guidelines for the design of clinical trials with longitudinal outcomes.

Sally Galbraith, Ian C Marschner, I. Marschner, 2002, Controlled clinical trials.

The number needed to treat (NNT) can be adjusted for bias when the outcome is measured with error.

I. Marschner, L. Irwig, S. Walter, 2004, Journal of clinical epidemiology.

Heterogeneity among susceptibles in epidemic models

I. Marschner, 1991 .

A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer.

I. Marschner, T. Dobbins, R. Ward, 2011, European journal of cancer.

Increase in Cholesterol Predicts Survival Advantage in Renal Cell Carcinoma Patients Treated with Temsirolimus

I. Marschner, R. Simes, B. Egleston, 2012, Clinical Cancer Research.

A Randomized Controlled Trial of Exercise and Manipulative Therapy for Cervicogenic Headache

I. Marschner, J. Emberson, C. Richardson, 2002, Spine.

Unexplained international differences in clinical outcomes after acute myocardial infarction and fibrinolytic therapy: lessons from the Hirulog and Early Reperfusion or Occlusion (HERO)-2 trial.

R. Califf, R. Diaz, I. Marschner, 2010, American heart journal.

Bayesian projection of the acquired immune deficiency syndrome epidemic

Susan R. Wilson, Niels Keiding, Ingrid K. Glad, 2002 .

Distributional regression in clinical trials: treatment effects on parameters other than the mean

I. Marschner, G. Heller, K. Robledo, 2022, BMC Medical Research Methodology.

Parametric conditional frailty models for recurrent cardiovascular events in the lipid study

I. Marschner, A. Tonkin, J. Simes, 2008, Clinical trials.

Design and rationale of a study in Asia of atorvastatin pretreatment in patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes.

I. Marschner, Y. Jang, J. Ge, 2010, Journal of cardiology.

Measurement error bias in pharmaceutical cost‐effectiveness analysis

Ian C. Marschner, I. Marschner, 2006 .

The Mechanism of Fibrinolysis Induced by Bacterial Pyrogens

I. Marschner, E. Deutsch, P. Elsner, 1959, Thrombosis and Haemostasis.